Maria Montserrat Aguilar-Hernandez1, Julio César Rincon Camacho2, Gabriela Galicia Garcia2. 1. Departamento de Hematología, Catedra CONACYT, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Avenida Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan C.P, 14080, Mexico City, Mexico. mmaguilarhe@conacyt.mx. 2. Departamento de Hematología, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Avenida Vasco de Quiroga No. 15, Colonia Belisario Domínguez Sección XVI, Delegación Tlalpan C.P, 14080, Mexico City, Mexico.
Abstract
PURPOSE OF REVIEW: Many prognostic and predictive biomarkers have been proposed for chronic lymphocytic leukaemia (CLL). Here, we aim to discuss the evidence showing a prognostic potential for extracellular vesicles (EV) and their associated microRNAs (miRNAs). RECENT FINDINGS: EV are produced by several cells in the body as a physiological event; however, there is evidence suggesting that an elevated EV concentration is present in the circulation of CLL patients. Moreover, some studies have associated EV concentration with advanced Rai stage and unmutated CLL while others have demonstrated its potential as an independent prognostic factor for TTFT and OS. Finally, some studies have shown that CLL EV shared some dysregulated microRNAs with CLL cells and plasma. On the other hand, it was found that CLL EV has a distinctive microRNA expression profile. Until now, EV-associated miR-155 is the most studied miRNA. Despite methodological diversity and limitations in study design, unanimity in CLL EV concentration behaviour and miRNA content has been found.
PURPOSE OF REVIEW: Many prognostic and predictive biomarkers have been proposed for chronic lymphocytic leukaemia (CLL). Here, we aim to discuss the evidence showing a prognostic potential for extracellular vesicles (EV) and their associated microRNAs (miRNAs). RECENT FINDINGS: EV are produced by several cells in the body as a physiological event; however, there is evidence suggesting that an elevated EV concentration is present in the circulation of CLL patients. Moreover, some studies have associated EV concentration with advanced Rai stage and unmutated CLL while others have demonstrated its potential as an independent prognostic factor for TTFT and OS. Finally, some studies have shown that CLL EV shared some dysregulated microRNAs with CLL cells and plasma. On the other hand, it was found that CLL EV has a distinctive microRNA expression profile. Until now, EV-associated miR-155 is the most studied miRNA. Despite methodological diversity and limitations in study design, unanimity in CLL EV concentration behaviour and miRNA content has been found.
Entities:
Keywords:
B cell receptor; Bruton's tyrosine kinase; Rai staging system; TCL-1 mice; Y RNA; ZAP-70; absolute lymphocyte count; argonaute; cancer-associated fibroblasts; chronic lymphocytic leukemia; exosomes; extracellular vesicles; ibrutinib; idelalisib; immunoglobulin heavy chain variable region gene (IGHV); miR-155; miR-21; microRNA; monoclonal B lymphocytosis; monocytes; overall survival; phosphoinositide 3-kinase; small noncoding RNA; time to first treatment
Authors: G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245
Authors: H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter Journal: N Engl J Med Date: 2000-12-28 Impact factor: 91.245
Authors: Anna Guarini; Sabina Chiaretti; Simona Tavolaro; Roberta Maggio; Nadia Peragine; Franca Citarella; Maria Rosaria Ricciardi; Simona Santangelo; Marilisa Marinelli; Maria Stefania De Propris; Monica Messina; Francesca Romana Mauro; Ilaria Del Giudice; Robert Foà Journal: Blood Date: 2008-05-16 Impact factor: 22.113
Authors: Graça M Dores; William F Anderson; Rochelle E Curtis; Ola Landgren; Evgenia Ostroumova; Elizabeth C Bluhm; Charles S Rabkin; Susan S Devesa; Martha S Linet Journal: Br J Haematol Date: 2007-10-17 Impact factor: 6.998
Authors: J L Binet; A Auquier; G Dighiero; C Chastang; H Piguet; J Goasguen; G Vaugier; G Potron; P Colona; F Oberling; M Thomas; G Tchernia; C Jacquillat; P Boivin; C Lesty; M T Duault; M Monconduit; S Belabbes; F Gremy Journal: Cancer Date: 1981-07-01 Impact factor: 6.860